Sagimet Biosciences Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Sagimet Biosciences Inc. (SGMT) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $2.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-03-11
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2.00K.
- 2024-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2.00K.
- 2023-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1.00K.
- 2023-09-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $3.00K.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $2.00K 10-K · filed 2026-03-11 |
| 2024-12-31 | $2.00K 10-K · filed 2025-03-12 |
| 2023-12-31 | $1.00K 10-K · filed 2024-03-25 |
| 2023-09-30 | $3.00K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $5.00K 10-Q · filed 2023-08-21 |
| 2022-12-31 | $26.00K 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |